Dihydroergotamine in prevention of infusion thrombophlebitis. A randomized trial.
The efficiency of subcutaneous dihydroergotamine in preventing infusion thrombophlebitis was assessed in a randomized trial. One hundred and fourteen postoperative patients were studied. They furnished a total of 160 infusion sites. The difference between treatment and control group with regard to incidence of infusion thrombophlebitis was not significant (p greater than 0.05). Accordingly dihydroergotamine has no substantial effect.